论文部分内容阅读
目的 本文观察了羟基喜树碱 (HCPT)、氨甲蝶呤 (MTX)、5 氟脲嘧啶 (5 Fu)和醛氢叶酸钙(LV)联合方案治疗晚期肺腺癌的疗效及毒副作用。方法 化疗方案为羟基喜树碱 8mg m2 静脉滴注 ,第 1～ 5天 ;氨甲蝶呤 10 0mg静脉推注 ,第 1日 ;醛氢叶酸钙 15 0mg m2 第 2～ 4天 ,静脉滴注 ;5 氟脲嘧啶5 0 0mg m2 静脉滴注 ,第 1～ 5天 ;2 8d为 1周期 ,连用 2个周期以上。结果 HMLF方案治疗晚期肺腺癌5 1例 ,总有效率 49% ,1年生存率 41% ,中位生存期为 11个月。主要毒副作用为轻度的血液和消化道反应。结论 羟基喜树碱为主的HMLF方案是治疗晚期肺腺癌有效且毒性较小的联合化疗方案
Objectives To observe the efficacy and side effects of HCPT, MTX, 5Fu, and LVF in the treatment of advanced lung adenocarcinoma. The method of chemotherapy was hydroxycamptothecine 8mg m2 intravenous drip, the first 1 to 5 days; Methotrexate 10Omg intravenous injection, the first day; Aldehyde and calcium folic acid 15Omg m2 2nd to 4th days, intravenous drip ;5 Fluorouracil 500 mg m2 intravenous drip, the first 1-5 days; 28 days is a cycle, with more than 2 cycles. Results The HMLF regimen was used to treat 51 cases of advanced lung adenocarcinoma with a total effective rate of 49%, a 1-year survival rate of 41%, and a median survival of 11 months. The main toxic side effects are mild blood and digestive tract reactions. Conclusion Hydroxycamptothecine-based HMLF is an effective and less toxic combination chemotherapy for advanced lung adenocarcinoma